Sha Hu1,2,#, Wenjing Wang1,#, Qianfang Hu3,#, Rujuan Zheng1,2, Qinghe Huang1,2, Hui Shi1,2, Xinyuan Ding3,*, Wenjuan Wang1,2,*, Zengyan Zhu1,2,*
Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.068967
- 19 January 2026
Abstract Objectives: Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the molecular and pharmacological mechanisms promoting paclitaxel resistance in NSCLC and to explore potential strategies for overcoming this resistance. Methods: Here, we report an integrated pharmacological and analytical approach to quantify paclitaxel disposition and overcome resistance in a A549/TAX cell model (paclitaxel-resistant A549 cells). Results: Cell counting kit-8 (CCK-8) assay, colony formation, and apoptosis assays confirmed that A549/TAX cells exhibited marked resistance to paclitaxel relative to parental A549 cells. Based on… More >
Login
Register
